The efficacy and safety of ZN-c3 is currently being evaluated in adult women with recurrent or persistent uterine serous carcinoma in an ongoing open-label, multicenter phase 2 study ...

January 28, 2013 Pulmonary Fibrosis After Pegylated Liposomal Doxorubicin in a Patient With Uterine Papillary Serous Carcinoma Authors: Nicole S. Nevadunsky [email protected], Chinyere Mbagwu ...

Objective To determine the outcomes of surgically staged patients with I-IIIA uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CCC) of the uterus treated at Indiana University and ...

By contrast, type II EC, which includes uterine serous cancer (USC), clear cell cancer and grade 3 endometrioid carcinoma, typically occurs in older, thinner patients and is not hormone dependent.

Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...

Several studies have shown that endometrial serous carcinoma has significantly less CD44 expression than endometrial endometrioid adenocarcinoma. 19, 20 The loss of CD44 expression has been ...

Uterine serous carcinoma is an aggressive variant of endometrial cancer that accounts for less than 10% of all endometrial cancers, yet 80% of endometrial cancer–related deaths.

Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma Drug showed reduced risk of disease or death and significantly improved ...